When Determining the Costs of a Valid, Experimental Evaluation of a New

Multiple Choice

When determining the costs of a valid, experimental evaluation of a new medical treatment, innovators often overlook the costs of

A) making a Type II error.
B) data collection.
C) monitoring the program and control groups participants.
D) not setting the probability of a Type I error accurately.